Long-term osteoporosis drug therapy reduces fracture risk in women but may increase risk for rare adverse events, and research gaps surround use of long-term drug therapies for osteoporotic fracture prevention.
Rates of osteoporosis screening and treatment are low in patients with recent stroke despite elevated risk for low-trauma fracture.
Cortical bidirectional axial transmission measurements may be useful for fracture risk assessment in postmenopausal women.
A meta-analysis showed that abaloparatide treatment reduces the risk for vertebral, nonvertebral, and wrist fractures in postmenopausal women with osteoporosis compared with placebo or other medical treatments.
Overall, treatments that were associated with the greatest relative risk reduction in fragility fractures included teriparatide, abaloparatide, denosumab, romosozumab and most bisphosphonate.
In elderly patients with COPD, rapid decline in bone mineral density is associated with an increased risk for vertebral fracture.
Multiple pharmacologic therapies have been shown to reduce fracture rates in postmenopausal women with acceptable safety profiles
Investigators examined the risk for diabetes-related fracture in a multiethnic population.
The discontinuation of denosumab is associated with increased bone turnover markers and bone loss, but prior treatment with bisphosphonates did not seem to prevent the development of these complications.
A biomechanical computed tomography program used to screen for osteoporosis appears to be a cost-effective alternative to standard care for adults age ≥65 years.
